Taysha gene therapies announces first patient dosed with tsha-102 in the reveal phase 1/2 trial under investigation for the treatment of rett syndrome

The phase 1/2 reveal trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of tsha-102 in adults with rett syndrome

TSHA Ratings Summary

TSHA Quant Ranking